Seer (SEER) Projected to Release Earnings on Wednesday

Seer (NASDAQ:SEER) is expected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Seer to announce earnings of ($0.27) per share and revenue of $3.55 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Seer (NASDAQ:SEER) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, meeting analysts’ consensus estimates of ($0.30). Seer had a negative return on equity of 26.58% and a negative net margin of 464.78%.The company had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $3.60 million.

Seer Stock Up 8.6%

NASDAQ SEER opened at $2.14 on Wednesday. Seer has a twelve month low of $1.55 and a twelve month high of $2.41. The company has a market cap of $117.66 million, a price-to-earnings ratio of -1.73 and a beta of 1.59. The business’s fifty day moving average is $1.88 and its 200 day moving average is $1.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Occudo Quantitative Strategies LP bought a new position in shares of Seer during the second quarter worth about $25,000. Marshall Wace LLP bought a new stake in Seer in the fourth quarter valued at approximately $85,000. Quadrature Capital Ltd acquired a new stake in Seer during the 4th quarter valued at approximately $101,000. Barclays PLC raised its holdings in Seer by 685.0% during the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock worth $111,000 after purchasing an additional 52,982 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new position in Seer during the 4th quarter worth approximately $116,000. 75.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SEER has been the subject of several research reports. TD Cowen upgraded Seer to a “strong-buy” rating in a research report on Monday, April 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a report on Friday, July 17th. Finally, Canaccord Genuity Group initiated coverage on Seer in a research note on Monday, May 4th. They issued a “buy” rating and a $4.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $4.00.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.